Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | SGK1 | O00141 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2118028 | 0.87 | MAPT (0.42) | MAPTRXFP1TP53SMN1; SMN2HSD11B1 | |
| SCHEMBL2117319 | 0.86 | ACLY (0.50) | MAPTRXFP1HSD11B1ACLY | |
| SCHEMBL2119228 | 0.83 | MAPT (0.54) | MAPTTP53SMN1; SMN2PIK3CAMTOR | |
| SCHEMBL2122713 | 0.82 | HSD11B1 (0.47) | MAPTTP53SMN1; SMN2HSD11B1PIK3CA | |
| SCHEMBL2119726 | 0.82 | KDM1A (0.48) | MAPTTP53SMN1; SMN2HSD11B1PIK3CA | |
| SCHEMBL2119034 | 0.82 | TP53 (0.52) | MAPTTP53SMN1; SMN2HSD11B1ACLY | |
| SCHEMBL2117860 | 0.81 | HSD11B1 (0.40) | MAPTTP53SMN1; SMN2HSD11B1PIK3CA | |
| SCHEMBL2117136 | 0.81 | TP53 (0.42) | MAPTTP53SMN1; SMN2HSD11B1PIK3CA | |
| SCHEMBL2117492 | 0.80 | KDM1A (0.40) | RXFP1HSD11B1PIK3CAMTORACLY | |
| SCHEMBL2120392 | 0.80 | PIK3CA (0.43) | MAPTHSD11B1PIK3CAMTORACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | MAPT 4747/4885RXFP1 1064/4885TP53 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.